-
公开(公告)号：US10889640B2
公开(公告)日：2021-01-12
申请号：US16409945
申请日：2019-05-13
Applicant: UCB BIOPHARMA SPRL
Inventor： David Edward Ormonde Knight , Terence Seward Baker , David James McMillan , Robert Anthony Griffin , Georges Mairet-Coello , Patrick Downey , Jean-Philippe Courade
Abstract: The present invention relates to Tau-binding antibodies and binding fragments thereof.
-
2.发明授权公开(公告)号：US09266953B2
公开(公告)日：2016-02-23
申请号：US14585406
申请日：2014-12-30
Applicant: UCB BIOPHARMA SPRL
Inventor： Helene Margaret Finney , Terence Seward Baker , Alastair David Griffiths Lawson , Karen Margrete Miller , Marc Roger de Ryck , Christian Gilbert J. Wolff
IPC: A61K39/395 , C12P21/08 , C07K16/00 , C07K16/28 , A61K39/00
CPC classification number: C07K16/28 , A61K39/3955 , A61K2039/505 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/76
Abstract: A Nav1.7 binding entity that after binding functionally modifies the activity of the ion channel, in particular an anti-Nav1.7 antibody or binding fragment thereof, pharmaceutical compositions comprising said antibodies, use of the antibodies and compositions comprising the same, in treatment, for example in the treatment/modulation of pain and processes for generating and preparing said antibodies.
Abstract translation: 结合后的Nav1.7结合实体功能性地修饰离子通道的活性，特别是抗Nav1.7抗体或其结合片段，包含所述抗体的药物组合物，使用抗体及其组合物在治疗中 ，例如在疼痛的治疗/调节中以及产生和制备所述抗体的方法。
-
公开(公告)号：US10344081B2
公开(公告)日：2019-07-09
申请号：US15742070
申请日：2016-07-05
Applicant: UCB BIOPHARMA SPRL
Inventor： Kerry Louise Tyson , Terence Seward Baker , Georges Mairet-Coello , Patrick Downey , Jean-Philippe Courade , David Edward Ormonde Knight
Abstract: The present invention relates to Tau-binding antibodies and binding fragments thereof.
-
公开(公告)号：US10112996B2
公开(公告)日：2018-10-30
申请号：US15014145
申请日：2016-02-03
Applicant: UCB Biopharma SPRL
Inventor： Helene Margaret Finney , Terence Seward Baker , Alastair David Griffiths Lawson , Karen Margrete Miller , Marc Roger de Ryck , Christian Gilbert J. Wolff
IPC: A61K39/395 , C07K16/28 , C07K16/00 , A61K39/00
Abstract: A Nav1.7 binding entity that after binding functionally modifies the activity of the ion channel, in particular an anti-Nav1.7 antibody or binding fragment thereof, pharmaceutical compositions comprising said antibodies, use of the antibodies and compositions comprising the same, in treatment, for example in the treatment/modulation of pain and processes for generating and preparing said antibodies.
-
公开(公告)号：US09738710B2
公开(公告)日：2017-08-22
申请号：US14547291
申请日：2014-11-19
Applicant: UCB Biopharma SPRL
Inventor： Karen Margrete Miller , Marc Roger De Ryck , Christian Gilbert J. Wolff , Alastair David Griffiths Lawson , Helene Margaret Finney , Terence Seward Baker
CPC classification number: C07K16/18 , C07K16/28 , C07K2317/34
Abstract: An anti-E1 ion channel antibody or binding fragment thereof, pharmaceutical compositions comprising said antibodies, use of the antibodies and compositions comprising the same, in treatment, for example in the treatment/modulation of pain and processes for generating and preparing said antibodies.
-
Patent Agency Ranking
公开(公告)号：US20200168293A1
公开(公告)日：2020-05-28
申请号：US15781228
申请日：2016-12-01
Applicant: UCB Biopharma SPRL
Inventor： Terence Seward Baker , Xiaofeng Liu , Jiye Shi , Richard David Taylor
Abstract: Computer-implemented methods of designing an antibody that will bind to a target epitope are disclosed. In one arrangement, the method comprises identifying one or more hotspot residues that will each bind to a corresponding one of one or more hotspot sites on the target epitope. Candidate antibody structures are selected from a database such that characteristic atoms within the antibody structure and hotspot characteristic atoms can be superimposed computationally with an averaged spatial deviation less than a predetermined threshold. A designed antibody is generated by replacing matching residues with different residues such that a predicted affinity is increased.
-
公开(公告)号：US20190298859A1
公开(公告)日：2019-10-03
申请号：US16337243
申请日：2017-09-27
Applicant: UCB Biopharma SPRL
Inventor： Terence Seward Baker , Michael Anthony William Eaton , Timothy John Norman , James Petrie Turner
Abstract: Compounds of formula (I), wherein Ar is an aryl group optionally further substituted with one or more groups R3; A is a lipophilic, hydrophobic moiety; R1 is a phosphodiester, phosphotriester, thioether or amide group; X is an unsubstituted or substituted C6 to C24 alkylene or alkenylene group, which is optionally interrupted by one or more —NR9—, —O— or —S— linkages, R2 is —YC(R4)(R5)CO2R6; and pharmaceutically acceptable salts or solvates thereof are useful as endosomolytic agents particularly for the delivery of nucleic acids useful in gene therapy.
-
公开(公告)号：US20150232553A1
公开(公告)日：2015-08-20
申请号：US14585406
申请日：2014-12-30
Applicant: UCB BIOPHARMA SPRL
Inventor： Helene Margaret Finney , Terence Seward Baker , Alastair David Griffiths Lawson , Karen Margrete Miller , Marc Roger de Ryck , Christian Gilbert J. Wolff
IPC: C07K16/28
CPC classification number: C07K16/28 , A61K39/3955 , A61K2039/505 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/76
Abstract: A Nav1.7 binding entity that after binding functionally modifies the activity of the ion channel, in particular an anti-Nav1.7 antibody or binding fragment thereof, pharmaceutical compositions comprising said antibodies, use of the antibodies and compositions comprising the same, in treatment, for example in the treatment/modulation of pain and processes for generating and preparing said antibodies.
Abstract translation: 结合后的Nav1.7结合实体功能性地修饰离子通道的活性，特别是抗Nav1.7抗体或其结合片段，包含所述抗体的药物组合物，使用抗体及其组合物在治疗中 ，例如在疼痛的治疗/调节中以及产生和制备所述抗体的方法。
-
公开(公告)号：US20150203571A1
公开(公告)日：2015-07-23
申请号：US14547291
申请日：2014-11-19
Applicant: UCB BIOPHARMA SPRL
Inventor： Karen Margrete Miller , Marc Roger De Ryck , Christian Gilbert J. Wolff , Alastair David Griffiths Lawson , Helene Margaret Finney , Terence Seward Baker
IPC: C07K16/18
CPC classification number: C07K16/18 , C07K16/28 , C07K2317/34
Abstract: An anti-E1 ion channel antibody or binding fragment thereof, pharmaceutical compositions comprising said antibodies, use of the antibodies and compositions comprising the same, in treatment, for example in the treatment/modulation of pain and processes for generating and preparing said antibodies.
Abstract translation: 抗E1离子通道抗体或其结合片段，包含所述抗体的药物组合物，抗体及其组合物的使用，例如用于治疗/调节疼痛以及产生和制备所述抗体的方法。
-
公开(公告)号：US09988446B2
公开(公告)日：2018-06-05
申请号：US14690892
申请日：2015-04-20
Applicant: UCB Biopharma SPRL
Inventor： Ralph Adams , Terence Seward Baker , Alastair David Griffiths Lawson
IPC: A61K39/395 , C07K16/24
CPC classification number: C07K16/244 , C07K2317/33 , C07K2317/92
Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
-
-
-
-
-
-
-
-
-
Search Results
17
records
(took 0.018 seconds)
